Top

Published in:

11-10-2023 | Bone Metastasis | RESEARCH ARTICLE

The prognosis and treatment of newly diagnosed bone metastasis of head and neck squamous cell cancer: an analysis of racial disparity

Authors: Huimei Huang, Shiying Zeng, Xiaojun Tang, Qian Yang, Yuexiang Qin, Qinglai Tang, Danhui Yin, Shisheng Li, Gangcai Zhu

Published in: Clinical and Translational Oncology | Issue 4/2024

Abstract

Objective

There is a lack of research investigating racial disparity in newly diagnosed head and neck squamous cell carcinoma with isolated bone metastases (HNSCC-BM). This study aims to investigate the clinical characteristics and prognostic factors in HNSCC-BM patients from different racial backgrounds to aid clinical decision making and management.

Methods

We retrieved data from the Surveillance, Epidemiology, and End Results (SEER) database for 345 cases of HNSCC-BM that were diagnosed between 2010 and 2017. Survival was compared using univariate and multivariate Cox proportional hazards models, Kaplan–Meier analysis, and log-rank tests. We also used propensity score matching to adjust for confounders.

Results

In white patients, those who were over 40 years of age had a significantly shorter survival (HR, 4.49; 95% CI 1.03–19.56; P < 0.05). Female black patients were found to survive longer compared to male patients (HR, 0.34; 95% CI 0.15–0.76; P < 0.01). Single (never married) Asians had shorter survival than married Asians (HR, 4.68; 95% CI 1.34–16.41; P < 0.05). In all three racial groups, patients who received radiotherapy in addition to chemotherapy did not survive longer than those receiving chemotherapy (P > 0.05). In Asian patients, those who underwent surgery at the primary site combined with chemoradiotherapy had significantly better survival outcomes than those who received chemoradiotherapy (HR: 0.10, 95% CI 0.01–0.88; P = 0.01).

Conclusion

Prognostic factors differ between HNSCC-BM patients from different racial backgrounds.

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. https://doi.org/10.1038/s41572-020-00224-3.CrossRefPubMedPubMedCentral

Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22. https://doi.org/10.1016/S0140-6736(20)30925-9.CrossRef

Ganesh K, Massague J. Targeting metastatic cancer. Nat Med. 2021;27(1):34–44. https://doi.org/10.1038/s41591-020-01195-4.CrossRefPubMedPubMedCentral

Suzuki A, Kashiwagi N, Doi H, Ishii K, Doi K, Kitano M, et al. Patterns of bone metastases from head and neck squamous cell carcinoma. Auris Nasus Larynx. 2020;47(2):262–7. https://doi.org/10.1016/j.anl.2019.08.001.CrossRefPubMed

Sethi S, Lu M, Kapke A, Benninger MS, Worsham MJ. Patient and tumor factors at diagnosis in a multi-ethnic primary head and neck squamous cell carcinoma cohort. J Surg Oncol. 2009;99(2):104–8. https://doi.org/10.1002/jso.21190.CrossRefPubMed

Lee KK, Rishishwar L, Ban D, Nagar SD, Marino-Ramirez L, McDonald JF, et al. Association of genetic ancestry and molecular signatures with cancer survival disparities: a pan-cancer analysis. Cancer Res. 2022;82(7):1222–33. https://doi.org/10.1158/0008-5472.CAN-21-2105.CrossRefPubMedPubMedCentral

Melariri H, Els T, Oyedele O, Suttle TK, Bermosky KT, De Freitas A, et al. Prevalence of locoregional recurrence and survival post-treatment of head and neck cancers in Africa: a systematic review and meta-analysis. EClinicalMedicine. 2023;59: 101964. https://doi.org/10.1016/j.eclinm.2023.101964.CrossRefPubMedPubMedCentral

Kim HAJ, Zeng PYF, Sorgini A, Shaikh MH, Khan H, MacNeil D, et al. Tumor molecular differences associated with outcome disparities of Black patients with head and neck cancer. Head Neck. 2022;44(5):1124–35. https://doi.org/10.1002/hed.27007.CrossRefPubMedPubMedCentral

Zhang W, Edwards A, Flemington EK, Zhang K. Racial disparities in patient survival and tumor mutation burden, and the association between tumor mutation burden and cancer incidence rate. Sci Rep. 2017;7(1):13639. https://doi.org/10.1038/s41598-017-13091-y.CrossRefPubMedPubMedCentral

10.

Liang Z, Wu M, Wang P, Quan H, Zhao J. Updated racial disparities in incidence, clinicopathological features and prognosis of hypopharyngeal squamous carcinoma in the United States. PLoS ONE. 2023;18(3): e0282603. https://doi.org/10.1371/journal.pone.0282603.CrossRefPubMedPubMedCentral

11.

Qureshi MM, Romesser PB, Ajani A, Kachnic LA, Jalisi S, Truong MT. Race disparities attributed to volumetric tumor burden in patients with head and neck cancer treated with radiotherapy. Head Neck. 2016;38(1):126–34. https://doi.org/10.1002/hed.23863.CrossRefPubMed

12.

Bhandari V, Jain RK. A retrospective study of incidence of bone metastasis in head and neck cancer. J Cancer Res Ther. 2013;9(1):90–3. https://doi.org/10.4103/0973-1482.110385.CrossRef

13.

Sakisuka T, Kashiwagi N, Doi H, Takahashi H, Arisawa A, Matsuo C, et al. Prognostic factors for bone metastases from head and neck squamous cell carcinoma: a case series of 97 patients. Mol Clin Oncol. 2021;15(5):246. https://doi.org/10.3892/mco.2021.2408.CrossRefPubMedPubMedCentral

14.

Lk Wong B, Wei Chern Gan R, Adabavazeh B, Jose J. Bone marrow metastasis/carcinomatosis in head and neck squamous cell carcinoma. J Oral Pathol Med. 2021;50(10):955–61. https://doi.org/10.1111/jop.13184.CrossRefPubMed

15.

Tang E, Lahmi L, Meillan N, Pietta G, Albert S, Maingon P. Treatment strategy for distant synchronous metastatic head and neck squamous cell carcinoma. Curr Oncol Rep. 2019;21(11):102. https://doi.org/10.1007/s11912-019-0856-5.CrossRefPubMed

16.

Mazul AL, Naik AN, Zhan KY, Stepan KO, Old MO, Kang SY, et al. Gender and race interact to influence survival disparities in head and neck cancer. Oral Oncol. 2021;112: 105093. https://doi.org/10.1016/j.oraloncology.2020.105093.CrossRefPubMed

17.

Groome PA, Schulze KM, Keller S, Mackillop WJ. Demographic differences between cancer survivors and those who die quickly of their disease. Clin Oncol (R Coll Radiol). 2008;20(8):647–56. https://doi.org/10.1016/j.clon.2008.05.006.CrossRefPubMed

18.

Liu K, Lin C, Zhang L. Novel prediction models for patients with oral squamous cell carcinoma at different anatomical sites. J Oral Maxillofac Surg. 2021;79(11):2358–69. https://doi.org/10.1016/j.joms.2021.06.023.CrossRefPubMed

19.

Massa ST, Cass LM, Challapalli S, Zahirsha Z, Simpson M, Ward G, et al. Demographic predictors of head and neck cancer survival differ in the elderly. Laryngoscope. 2019;129(1):146–53. https://doi.org/10.1002/lary.27289.CrossRefPubMed

20.

Massa ST, Osazuwa-Peters N, Christopher KM, Arnold LD, Schootman M, Walker RJ, et al. Competing causes of death in the head and neck cancer population. Oral Oncol. 2017;65:8–15. https://doi.org/10.1016/j.oraloncology.2016.12.006.CrossRefPubMed

21.

Lorenz FJ, Mahase SS, Miccio J, King TS, Pradhan S, Goyal N. Update on adherence to guidelines for time to initiation of postoperative radiation for head and neck squamous cell carcinoma. Head Neck. 2023;45(7):1676–91. https://doi.org/10.1002/hed.27380.CrossRefPubMedPubMedCentral

22.

Martinez ME, Anderson K, Murphy JD, Hurley S, Canchola AJ, Keegan TH, et al. Differences in marital status and mortality by race/ethnicity and nativity among California cancer patients. Cancer. 2016;122(10):1570–8. https://doi.org/10.1002/cncr.29886.CrossRefPubMed

23.

Duprez F, Berwouts D, De Neve W, Bonte K, Boterberg T, Deron P, et al. Distant metastases in head and neck cancer. Head Neck. 2017;39(9):1733–43. https://doi.org/10.1002/hed.24687.CrossRefPubMed

24.

Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016;34(24):2835–42. https://doi.org/10.1200/JCO.2016.67.4788.CrossRefPubMed

25.

Alvegard T. Bone sarcomas. Acta Oncol. 1996;35(Suppl 7):123–4. https://doi.org/10.3109/02841869609101672.CrossRefPubMed

26.

Coleman RE, Croucher PI, Padhani AR, Clezardin P, Chow E, Fallon M, et al. Bone metastases. Nat Rev Dis Primers. 2020;6(1):83. https://doi.org/10.1038/s41572-020-00216-3.CrossRefPubMed

27.

Kabarriti R, Baliga S, Ohri N, Guha C, Kalnicki S, Garg MK. Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma. Head Neck. 2019;41(1):130–8. https://doi.org/10.1002/hed.25476.CrossRefPubMed

28.

Williams DR, Rucker TD. Understanding and addressing racial disparities in health care. Health Care Financ Rev. 2000;21(4):75–90.

29.

The LO. Racial disparities in cancer care: can we close the gap? Lancet Oncol. 2021;22(12):1643. https://doi.org/10.1016/S1470-2045(21)00669-0.CrossRef

30.

Levey AS, Powe NR. eGFR and chemotherapy: will removing race create disparities? Lancet Oncol. 2021;22(9):1208–9. https://doi.org/10.1016/S1470-2045(21)00391-0.CrossRefPubMed

31.

Bajaj SS, Jain B, Potter AL, Dee EC, Yang CJ. Racial and ethnic disparities in end-of-life care for patients with oesophageal cancer: death trends over time. Lancet Reg Health Am. 2023;17: 100401. https://doi.org/10.1016/j.lana.2022.100401.CrossRefPubMed

Title: The prognosis and treatment of newly diagnosed bone metastasis of head and neck squamous cell cancer: an analysis of racial disparity
Authors: Huimei Huang
Shiying Zeng
Xiaojun Tang
Qian Yang
Yuexiang Qin
Qinglai Tang
Danhui Yin
Shisheng Li
Gangcai Zhu
Publication date: 11-10-2023
Publisher: Springer International Publishing
Keywords: Bone Metastasis
Metastasis
Radiotherapy
Cytostatic Therapy
Published in: Clinical and Translational Oncology / Issue 4/2024
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-023-03327-x

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

Perioperative chemo outplays neoadjuvant CRT in esophageal cancer

05-06-2024 Esophageal Cancer News

LAURA heralds practice change for locally advanced NSCLC

03-06-2024 NSCLC News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2024

Acknowledgement to reviewers: 2023

Myelodysplastic syndromes mortality in Spain: a comprehensive age-period-cohort and joinpoint analysis

Comprehensive profiling of enhancer RNA in stage II/III colorectal cancer defines two prognostic subtypes with implications for immunotherapy

Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy

Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review